HBP Share Price

Open 0.84 Change Price %
High 0.84 1 Day 0.00 0.00
Low 0.84 1 Week 0.00 0.00
Close 0.84 1 Month -0.06 -6.67
Volume 2500 1 Year -0.66 -44.00
52 Week High 1.65
52 Week Low 0.70
HBP Important Levels
Resistance 2 0.84
Resistance 1 0.84
Pivot 0.84
Support 1 0.84
Support 2 0.84
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
ECA 15.09 4.43%
ECA 15.09 4.43%
ECA 15.09 4.43%
SC 60.83 -0.44%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
GGA 0.06 20.00%
ANX 0.07 16.67%
ANX 0.07 16.67%
COM 2.27 14.07%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
NXJ 2.35 -10.31%
NXJ 2.35 -10.31%
RN 0.09 -10.00%
RN 0.09 -10.00%
CTU-A 0.19 -9.52%
TNP 0.90 -9.09%
TNP 0.90 -9.09%
TNX 0.34 -8.11%
QEC 0.74 -7.50%
More..

Helix BioPharma Corp (TSE: HBP)

HBP Technical Analysis 5
As on 30th Oct 2017 HBP Share Price closed @ 0.84 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.45 & Strong Sell for SHORT-TERM with Stoploss of 0.93 we also expect STOCK to react on Following IMPORTANT LEVELS.
HBP Target for November
1st Target up-side 0.89
2nd Target up-side 0.92
3rd Target up-side 0.96
1st Target down-side 0.79
2nd Target down-side 0.76
3rd Target down-side 0.72
HBP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.helixbiopharma.com
HBP Address
HBP
305 Industrial Parkway South
Unit 3
Aurora, ON L4G 6X7
Canada
Phone: 905-841-2300
Fax: 905-841-2244
HBP Latest News
Interactive Technical Analysis Chart Helix BioPharma Corp ( HBP TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Helix BioPharma Corp
HBP Business Profile
Helix BioPharma Corp., a biopharmaceutical company, develops drugs for the prevention and treatment of cancer based on its proprietary technologies. The company focuses on the development of L-DOS47 that is in phase I/II clinical trial for the treatment of inoperable, locally advanced, and recurrent or metastatic non-small cell lung cancer; and Topical Interferon Alpha-2b, which has completed phase II study for the treatment of low-grade cervical lesions and ano-genital warts caused by human papilloma virus infections. It also offers DOS47, a patented oncology platform technology that derives a therapeutic pharmacological effect by acting upon a naturally occurring substance in the body. Helix BioPharma Corp. is based in Aurora, Canada.